
    
      This is a Phase 1, multicenter, dose-escalation study evaluating the safety, tolerability and
      pharmacokinetics of the PARP inhibitor ABT-888 in combination with conventional whole brain
      radiation therapy (WBRT) in the treatment of subjects with solid tumors metastatic to the
      brain.
    
  